Results 41 to 50 of about 443 (130)

Serum rheumatoid factor IgA, anti-citrullinated peptide antibodies with secretory components, and anti-carbamylated protein antibodies associate with interstitial lung disease in rheumatoid arthritis

open access: yesBMC Musculoskeletal Disorders, 2022
Objective Rheumatoid arthritis (RA) is often complicated with chronic lung diseases (CLD), including interstitial lung disease (ILD) and airway disease, which occur as extra-articular manifestations.
Shomi Oka   +13 more
doaj   +1 more source

Evaluating the Diagnostic Accuracy of Rheumatoid Factor, Anti-citrullinated Protein Antibody and Anti-carbamylated Protein Antibody in Early Detection of Rheumatoid Arthritis: A Cross-sectional Study [PDF]

open access: yesJournal of Clinical and Diagnostic Research
Introduction: Rheumatoid Arthritis (RA) is a systemic autoimmune disease that primarily affects synovial joints. Joint infiltration with immune cells is a characteristic feature of RA.
Karthiga Dhakshna Murthi   +3 more
doaj   +1 more source

Added value of multiple autoantibody testing for predicting progression to inflammatory arthritis in at-risk individuals

open access: yesRMD Open, 2022
Background Predicting progression to clinical arthritis in individuals at-risk of developing rheumatoid arthritis is a prerequisite to developing stratification groups for prevention strategies. Selecting accurate predictive criteria is the critical step
Paul Emery   +7 more
doaj   +1 more source

The isotype and IgG subclass distribution of anti-carbamylated protein antibodies in rheumatoid arthritis patients

open access: yesArthritis Research & Therapy, 2017
Background Anti-carbamylated protein (anti-CarP) antibodies have recently been reported to occur in around 45% of rheumatoid arthritis (RA) patients and to have prognostic and diagnostic properties.
Myrthe A. M. van Delft   +8 more
doaj   +1 more source

Interactions between rheumatoid arthritis antibodies are associated with the response to anti-tumor necrosis factor therapy

open access: yesBMC Musculoskeletal Disorders, 2021
Background Blocking of the Tumor Necrosis Factor (TNF) activity is a successful therapeutic approach for 50–60% of rheumatoid arthritis (RA) patients. However, there are yet no biomarkers to stratify patients for anti-TNF therapy.
Antonio Julià   +19 more
doaj   +1 more source

Evolution of anti-modified protein antibody responses can be driven by consecutive exposure to different post-translational modifications

open access: yesArthritis Research & Therapy, 2021
Background Besides anti-citrullinated protein antibodies (ACPA), rheumatoid arthritis patients (RA) often display autoantibody reactivities against other post-translationally modified (PTM) proteins, more specifically carbamylated and acetylated proteins.
M. Volkov   +9 more
doaj   +1 more source

Value of Measuring Anti-Carbamylated Protein Antibodies for Classification on Early Arthritis Patients

open access: yesScientific Reports, 2017
Classification of patients with rheumatoid arthritis (RA) as quickly as possible improves their prognosis. This reason motivates specially dedicated early arthritis (EA) clinics.
Cristina Regueiro   +9 more
doaj   +1 more source

Anti-carbamylated protein antibody isotype pattern differs between palindromic rheumatism and rheumatoid arthritis

open access: yesTherapeutic Advances in Musculoskeletal Disease, 2020
Background: A restricted response against citrullinated peptides/proteins, with less isotype usage, has been found in palindromic rheumatism (PR) in comparison with rheumatoid arthritis (RA).
Raul Castellanos-Moreira   +14 more
doaj   +1 more source

Geo-epidemiology of autoantibodies in rheumatoid arthritis: comparison between four ethnically diverse populations

open access: yesArthritis Research & Therapy, 2023
Background Rheumatoid arthritis (RA) occurs across the globe in different ethnic populations. Most RA patients harbor anti-modified protein antibodies (AMPA); however, it is unclear whether differences exist in autoantibody responses at different ...
Emma C. de Moel   +10 more
doaj   +1 more source

Anti-carbamylated protein antibodies as a new biomarker of erosive joint damage in systemic lupus erythematosus

open access: yesArthritis Research & Therapy, 2018
Background The application of more sensitive imaging techniques, such as ultrasonography (US), changed the concept of non-erosive arthritis in systemic lupus erythematosus (SLE), underlining the need for biomarkers to identify patients developing the ...
Fulvia Ceccarelli   +11 more
doaj   +1 more source

Home - About - Disclaimer - Privacy